Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Stopped Early discontinuation based on strategic sponsor decision not driven by any safety concerns

Conditions

• Cancer
• Neoplasm

Interventions

• DRUG: SAR444881
• DRUG: Pembrolizumab
• DRUG: Cetuximab
• DRUG: Carboplatin
• DRUG: Pemetrexed

Sponsor

Sanofi